Positive Phase III Builds Case for Intra-Cellular’s Depression Drug

Intra-Cellular Therapies’ Caplyta met its primary endpoint in the Phase III Study 403 trial, easing the burden of depressive episodes in patients with major depressive disorder or bipolar depression.